Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Published

Journal Article

Development of effective therapies for recurrent glioblastoma multiforme (GBM) and reliable, timely evaluation of their benefit are needed. Understanding the relationship between objective response (OR) and survival is important for determining whether OR can provide an early signal of treatment activity in clinical trials. We performed a landmark analysis to evaluate the association between OR and survival at 9, 18, and 26 weeks for 167 patients with recurrent GBM who participated in BRAIN, a phase II trial that evaluated efficacy of bevacizumab alone or in combination with irinotecan, using the Cox regression models adjusted for age, baseline Karnofsky performance score, first vs second relapse, and treatment arm. Hazard ratios (HRs) and P-values for survival between responders and nonresponders were calculated. Additional analyses were performed to test robustness, validity, fit, and accuracy of the models. The relationships between progression-free survival (PFS) and survival and between OR and PFS were also explored. There were 55 responders and 112 nonresponders across the 2 treatment arms in BRAIN. OR status at 9, 18, and 26 weeks was a statistically significant predictor of survival (HR ≤ 0.52, P < .01). PFS was also a statistically significant predictor of survival at each landmark (HR ≤ 0.25, P < .0001). The association between OR and PFS was not statistically significant, likely due to inadequate statistical power for the analysis. Clarifying the relationship of OR and survival is important for determining whether OR can be a reliable predictor of the benefit of a therapeutic agent in patients with recurrent GBM.

Full Text

Duke Authors

Cited Authors

  • Prados, M; Cloughesy, T; Samant, M; Fang, L; Wen, PY; Mikkelsen, T; Schiff, D; Abrey, LE; Yung, WKA; Paleologos, N; Nicholas, MK; Jensen, R; Vredenburgh, J; Das, A; Friedman, HS

Published Date

  • January 2011

Published In

Volume / Issue

  • 13 / 1

Start / End Page

  • 143 - 151

PubMed ID

  • 21084434

Pubmed Central ID

  • 21084434

Electronic International Standard Serial Number (EISSN)

  • 1523-5866

Digital Object Identifier (DOI)

  • 10.1093/neuonc/noq151

Language

  • eng

Conference Location

  • England